Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Ophthalmology. 2009 Dec 6;117(2):356. doi: 10.1016/j.ophtha.2009.06.060

Table 2.

Therapeutic outcomes of cyclophosphamide therapy for inflammatory eye disease

Outcome Uveitis Scleritis Mucous Membrane Pemphigoid Other Total
Used as only immunosuppressive drug therapy 44 48 98 25 215
Treatment Success At Or Before 6 months, % (95% Confidence Interval(CI))
Controlled Inflammation - No Activity at 6 months 50.2 (33.8 - 69.2) 53.3 (37.4 - 71.0) 43.0 (33.0 - 54.5) 72.0 (49.1 - 91.0) 49.2 (41.7 - 57.2)
Controlled Inflammation - No Activity or Slightly Active at 6 months 52.5 (34.4 - 73.1) 61.5 (45.1 - 78.1) 56.4 (45.4 - 68.0) 78.0 (55.0 - 94.3) 58.9 (51.0 - 67.0)
Corticosteroid Sparing -Controlled Inflammation and Prednisone ≤ 10 mg/day 30.9 (18.3 - 49.1) 30.2 (17.8 - 48.1) 25.6 (17.6 - 36.3) 50.2 (29.1 - 75.7) 30.1 (23.8 - 37.6)
Corticosteroid Sparing -Controlled Inflammation and Prednisone ≤ 5 mg/day 29.4 (17.0 - 48.0) 17.9 (8.91 - 34.1) 19.7 (12.7 - 29.8) 33.6 (17.3 - 58.6) 22.8 (17.3 - 29.7)
Corticosteroid Sparing -Controlled Inflammation and Prednisone = 0 mg/day 5.71 (1.46 - 21.0) 0.00 (0.00 - 0.00) 2.22 (0.56 - 8.60) 10.7 (2.76 - 36.8) 3.31 (1.50 - 7.23)
Treatment Success At Or Before 12 months, % (95% CI)
Controlled Inflammation - No Activity at 12 months 81.3 (63.6 - 93.8) 82.2 (65.4 - 94.0) 68.7 (57.0 - 80.1) 89.5 (65.4 - 99.2) 76. 4 (68.3 - 83.7)
Controlled Inflammation - No Activity or Slightly Active at 12 months 88.9 (70.8 - 98.0) 80.0 (62.5 - 92.9) 80.8 (68.5 - 90.5) 89.0 (64.2 - 99.1) 83.4 (75.3 - 90.0)
Corticosteroid Sparing -Controlled Inflammation and Prednisone ≤ 10 mg/day 64.8 (46.5 - 82.6) 60.5 (44.0 - 77.5) 58.5 (46.8 - 70.6) 68.9 (43.6 - 90.7) 61.2 (53.0 - 69.5)
Corticosteroid Sparing -Controlled Inflammation and Prednisone ≤ 5 mg/day 49.1 (32.6 - 68.6) 37.8 (23.7 - 56.7) 48.4 (37.0 - 61.2) 64.6 (40.7 - 87.2) 47.8 (39.9 - 56.4)
Corticosteroid Sparing -Controlled Inflammation and Prednisone = 0 mg/day 16.2 (7.0 - 34.9) 15.9 (6.90 - 34.1) 7.65 (3.49 - 16.3) 23.5 (9.41 - 51.5) 12.6 (8.30 - 18.9)
HHS Vulnerability Disclosure